Biotech

All Articles

Actinogen's cortisol blocker falls short phase 2 clinical depression study

.Actinogen Medical's cortisol blocker has missed the key endpoint of a period 2 research study in de...

Bivictrix determines going exclusive only technique to take ADC into facility

.Antibody-drug conjugates (ADCs) have actually been at the facility of a lot of a billion-dollar bio...

TPG leadings up funds to $580M for expenditures throughout life scientific researches

.Resource manager TPG, which has sustained biotechs like Sionna Rehabs and Santa Ana Bio, has actual...

Merck ceases period 3 TIGIT test in bronchi cancer cells for futility

.Merck &amp Co.'s TIGIT plan has actually gone through yet another problem. Months after shuttering ...

After a hard year, Exscientia folds up in to Recursion

.After a year described by pipe hairstyles, the shift of its chief executive officer and also cutbac...

Cullinan, after $25M deal, hands back bispecific to Port

.Cullinan Therapeutics was thrilled enough along with Port BioMed's bispecific immune system reactor...

A better examine Strong Biotech's Brutal 15

.In this particular week's incident of "The Top Pipe," our team're diving into Intense Biotech's yea...

Lilly faces period 2 failure of tau-targeting med

.The confetti is actually still flying from Eli Lilly's gathering celebrating the approval of Alzhei...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our summary of considerable leadership hirings, shooting...

Lykos will definitely talk to FDA to reassess its own decision observing denial of MDMA treatment for trauma

.Observing an inadequate showing for Lykos Therapies' MDMA prospect for trauma at a recent FDA consu...